Your browser doesn't support javascript.
loading
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study.
Liu, Xiaofan; Zhou, Hu; Hu, Yu; Yin, Jie; Li, Junmin; Chen, Wenming; Huang, Ruibin; Gong, Yuping; Luo, Chengwei; Mei, Heng; Ding, Bingjie; Gu, Chengyuan; Sun, Huiping; Leng, Yun; Ji, Dexiang; Li, Yan; Yin, Hongyan; Shi, Haiyan; Chen, Keyan; Wang, Jian; Fan, Songhua; Su, Weiguo; Yang, Renchi.
Affiliation
  • Liu X; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy
  • Zhou H; Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
  • Hu Y; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Yin J; The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Li J; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Chen W; Beijing Chaoyang Hospital of Capital Medical University, Beijing, China.
  • Huang R; The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Gong Y; West China Hospital of Sichuan University, Chengdu, China.
  • Luo C; Guangdong Provincial People's Hospital, Guangzhou, China.
  • Mei H; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Ding B; Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
  • Gu C; The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Sun H; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Leng Y; Beijing Chaoyang Hospital of Capital Medical University, Beijing, China.
  • Ji D; The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Li Y; West China Hospital of Sichuan University, Chengdu, China.
  • Yin H; HUTCHMED, Shanghai, China.
  • Shi H; HUTCHMED, Shanghai, China.
  • Chen K; HUTCHMED, Shanghai, China.
  • Wang J; HUTCHMED, Shanghai, China.
  • Fan S; HUTCHMED, Shanghai, China.
  • Su W; HUTCHMED, Shanghai, China.
  • Yang R; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy
Lancet Haematol ; 10(6): e406-e418, 2023 Jun.
Article in En | MEDLINE | ID: mdl-37028433
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Purpura, Thrombocytopenic, Idiopathic Type of study: Clinical_trials / Guideline Limits: Adult / Female / Humans / Male Language: En Journal: Lancet Haematol Year: 2023 Document type: Article Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Purpura, Thrombocytopenic, Idiopathic Type of study: Clinical_trials / Guideline Limits: Adult / Female / Humans / Male Language: En Journal: Lancet Haematol Year: 2023 Document type: Article Country of publication: Reino Unido